Literature DB >> 9126962

Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines.

P R Beatty1, S M Krams, O M Martinez.   

Abstract

Immunocompromised individuals have an increased incidence of EBV-associated B cell lymphomas. The growth factors responsible for the unrestrained proliferation of these lymphomas have not yet been determined. In this study, spontaneous lymphoblastoid cell lines (SLCL) were derived without the addition of growth factors or virus from four patients with EBV-associated lymphoproliferative disorder. These cell lines were EBV transformed in vivo, and infection was verified through amplification of the viral gp220 gene. SLCL have an activated B cell phenotype (CD19+, CD21+, CD23+, CD38+, and CD40+) and produce IL-6, IL-10, TNF-alpha, and lymphotoxin-alpha. To determine whether these cytokines contribute to autonomous growth, neutralizing Abs for IL-10, IL-6, and TNF-alpha, a soluble TNFR:Fc fusion protein, and soluble IL-10R were used. These experiments established that, of the cytokines produced by SLCL, only IL-10 is an autocrine factor. IL-10 was produced by the majority of cells within each SLCL, and IL-10 secretion was concomitant with SLCL growth. Our findings demonstrate that IL-10 is utilized in the autonomous growth of EBV-related lymphomas and may be crucial in the development of lymphoproliferative disorder.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9126962

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

1.  Type 2 cytokines predominate in the human CD4(+) T-lymphocyte response to Epstein-Barr virus nuclear antigen 1.

Authors:  P Steigerwald-Mullen; M G Kurilla; T J Braciale
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

Review 2.  Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation.

Authors:  Francesco Pegoraro; Claudio Favre
Journal:  Ann Hematol       Date:  2021-02-06       Impact factor: 3.673

Review 3.  Theodore E. Woodward Award: development of novel, EBV-targeted therapies for EBV-positive tumors.

Authors:  Shannon Kenney
Journal:  Trans Am Clin Climatol Assoc       Date:  2006

Review 4.  Pathophysiology of retinal lymphoma.

Authors:  Sarah E Coupland; Chi Chao Chan; Justine Smith
Journal:  Ocul Immunol Inflamm       Date:  2009 Jul-Aug       Impact factor: 3.070

5.  Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model.

Authors:  Gregory K Hong; Margaret L Gulley; Wen-Hai Feng; Henri-Jacques Delecluse; Elizabeth Holley-Guthrie; Shannon C Kenney
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

Review 6.  The interplay between Epstein-Barr virus and B lymphocytes: implications for infection, immunity, and disease.

Authors:  Olivia L Hatton; Aleishia Harris-Arnold; Steven Schaffert; Sheri M Krams; Olivia M Martinez
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

Review 7.  A review on EBV encoded and EBV-induced host microRNAs expression profile in different lymphoma types.

Authors:  Saber Soltani; Armin Zakeri; Alireza Tabibzadeh; Amir Mohammad Zakeri; Milad Zandi; Saba Siavoshi; Saba Seifpour; Abbas Farahani
Journal:  Mol Biol Rep       Date:  2021-02-01       Impact factor: 2.316

8.  Toll-like receptor agonists synergistically increase proliferation and activation of B cells by epstein-barr virus.

Authors:  Stefanie Iskra; Markus Kalla; Henri-Jacques Delecluse; Wolfgang Hammerschmidt; Andreas Moosmann
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

9.  Tumor-derived variants of Epstein-Barr virus latent membrane protein 1 induce sustained Erk activation and c-Fos.

Authors:  Maria Vaysberg; Olivia Hatton; Stacie L Lambert; Andrew L Snow; Bonnie Wong; Sheri M Krams; Olivia M Martinez
Journal:  J Biol Chem       Date:  2008-11-05       Impact factor: 5.157

Review 10.  Interferon-alpha and its effects on post-transplant lymphoproliferative disorders.

Authors:  A Faro
Journal:  Springer Semin Immunopathol       Date:  1998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.